Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/5/2026

1. KRG
2. ALAR
3. SPY
4. PBA
5. CCH:LN
6. META
7. CCHGY
8. PRY:IM
9. PRYMY
10. SKA-B

Go back to Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
(NASDAQ: PTGX) Delayed: 131.62 +6.45 (5.15%)
Previous Close $125.17    52 Week High $24.52 
Open $125.89    52 Week Low $10.02 
Day High $131.87    P/E N/A 
Day Low $125.24    EPS $0.00 
Volume 708,390